Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Sponsor-Investigator (SI) FDA Inspections
Sponsor-Investigator (SI) FDA Inspections
by eurolsin
Christiana Provencal, M.A.. Quality Assurance / Qu...
Preparing for an FDA Inspection
Preparing for an FDA Inspection
by felicity
. Kathy Gilmartin, MSN, CRNP, CCRC. ...
Preparing for an FDA Inspection
Preparing for an FDA Inspection
by tawny-fly
. Kathy Gilmartin, MSN, CRN...
Preparing for an FDA Inspection
Preparing for an FDA Inspection
by min-jolicoeur
. Kathy Gilmartin, MSN, CRN...
ROMA – Overview and FDA Lessons
ROMA – Overview and FDA Lessons
by tristan742
Clinical Situation: . A woman with a pelvic mass. ...
FDA Regulatory Requirements for Successful Biomarker Applications
FDA Regulatory Requirements for Successful Biomarker Applications
by oliver
Early Detection Research Network. September 9, 201...
The FDA is Coming Neala Lane, MS, CCRC
The FDA is Coming Neala Lane, MS, CCRC
by joy
Associate Director. Quality Improvement Office. Of...
FDA Pre-Submission Meetings
FDA Pre-Submission Meetings
by violet
for 510(k) Submissions. Consultants and RA Experts...
Welcome Once you’ve logged into
Welcome Once you’ve logged into
by dora
Webex. , please select one of the following audio ...
Investigator Responsibilities for Research
Investigator Responsibilities for Research
by trish-goza
Shannon Simmons, BA, CIP. March 14, 2014. Process...
Everyday Preparedness for the
Everyday Preparedness for the
by tatiana-dople
Challenges . of . FDA-Regulated . Research. Pat W...
UC DAVIS OFFICE OF RESEARCH
UC DAVIS OFFICE OF RESEARCH
by olivia-moreira
Overview of Good Clinical Practices (GCP) . Inves...
1 Pediatric Clinical Investigator Training
1 Pediatric Clinical Investigator Training
by lois-ondreau
GCP: . Tips on Clinical Trial Conduct and . Prepa...
SHEDDING LIGHT ON AN
SHEDDING LIGHT ON AN
by olivia-moreira
SHEDDING LIGHT ON AN FDA VISIT Joyce Nancarrow Tu...
1 Structure and mandate of FDA
1 Structure and mandate of FDA
by sherrill-nordquist
Leonard Sacks. Office of Medical Policy. CDER, FD...
The IND and Clinical Trial Management
The IND and Clinical Trial Management
by kittie-lecroy
Frances Richmond . Director International Center ...
My Experiences as an FDA Statistician
My Experiences as an FDA Statistician
by aaron
Yeh-Fong Chen, Ph.D. . FDA/CDER/OB/DB3. CBA 2016-...
Clinical Trial Data Integrity:
Clinical Trial Data Integrity:
by phoebe-click
Bi. oresearch . Mo. nitoring Program. Jur Strobos...
Global Regulatory Affairs
Global Regulatory Affairs
by min-jolicoeur
US . vs. EU. Nariko Koto, MBA. Global Regulatory/...
educate • fund • connect • support
educate • fund • connect • support
by briana-ranney
MIAP – Introduction to INDs and IDEs. E Mitchel...
Would the FDA approve Normal Saline Today?
Would the FDA approve Normal Saline Today?
by yoshiko-marsland
Brad Nichol M.D.. Valley View Hospital. Would the...
The Rare Disease Treatment Approval Process:
The Rare Disease Treatment Approval Process:
by lily
Balancing Gold Standard Evidence with Patient-Cent...
Guidance for Clinical Investigators Sponsors and Investigational New D
Guidance for Clinical Investigators Sponsors and Investigational New D
by jade
NOTE A stay is in effect for partsof subsection V...
Registry Kobayashi Cardiology Childrens Hospital Associate Professor
Registry Kobayashi Cardiology Childrens Hospital Associate Professor
by nathanael
How Are They Set Up?. Daisuke Kobayashi, MD, MPH, ...
A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials
A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials
by adah
Jingjing Ye, PhD. BeiGene. PSI Journal Club: Bayes...
Regulatory Environment for
Regulatory Environment for
by mila-milly
Alzheimers. Therapeutics . (and Diagnostics). Mar...
Presentation To : The Jackson Laboratory
Presentation To : The Jackson Laboratory
by isla
Chris Hempel. Addi & Cassi Fund. A Family’s ...
Karen Davis-Bruno Ph.D (FDA/CDER/OND)
Karen Davis-Bruno Ph.D (FDA/CDER/OND)
by isabella2
Melissa Tassinari . Ph.D. (FDA/CDER/OND/DPMH). Jac...
Writing and Holding an IND- IIT Development
Writing and Holding an IND- IIT Development
by osullivan
Week 3- Proposing and Conducting a Clinical Trial....
TABLE OF CONTENTS
TABLE OF CONTENTS
by tracy
I. INTRODUCTION .....................................
Clinical/Surrogate Endpoints and Innovative Approaches for Catheter Ablation Studies
Clinical/Surrogate Endpoints and Innovative Approaches for Catheter Ablation Studies
by SugarPlumFairy
FDA Perspective. Marco Cannella, PhD. Senior Lead ...
Clinical and Nonclinical Inspections
Clinical and Nonclinical Inspections
by claire
n and Research or CBER conducting clinical resear...
Session 8: Study Start-up: Part 2
Session 8: Study Start-up: Part 2
by gabriella
Derita: . dbran@uthsc.edu. Margaret: . mlynn@ut...
A R egulatory Perspective on Threats
A R egulatory Perspective on Threats
by liane-varnes
to the . Integrity . of . Analgesic Clinical Tria...
Investigator Responsibilities for Research
Investigator Responsibilities for Research
by danika-pritchard
Jan Zolkower, MSHL, CIP, CCRP. January 13, 2012...
Navigating the differences between
Navigating the differences between
by liane-varnes
Investigator-Initiated . v. Sponsor-Initiated Cli...
Objectives
Objectives
by yoshiko-marsland
Identify consent . process . requirements. Distin...
Improving the process of rare disease treatment development
Improving the process of rare disease treatment development
by lindy-dunigan
“. EMERGING THERAPIES FOR RARE DISEASES. ”. ...
Navigating the differences between
Navigating the differences between
by celsa-spraggs
Investigator-Initiated . v. Sponsor-Initiated Cli...
Investigator Responsibilities for Research
Investigator Responsibilities for Research
by debby-jeon
Jan Zolkower, MSHL, CIP, CCRP. January 13, 2012...